Pfizer Inc. has beaten back a challenge to a new diabetes treatment that allows sufferers to administer insulin without using injections.
Southern District of New York Judge Leonard Sand, in Novo Nordisk v. Pfizer, 06 Civ. 5819, Thursday refused to grant a preliminary injunction against the drug Exubera, due to be launched in March 2007.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
For questions call 1-877-256-2472 or contact us at [email protected]